3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Sarcoma
43
Melanoma
19
Neoplasms
12
Squamous Cell Carcinoma of Head and Neck
11
Neoplasm Metastasis
11
Carcinoma, Non-Small-Cell Lung
9
Breast Neoplasms
9
Glioblastoma
8
Colorectal Neoplasms
8
Triple Negative Breast Neoplasms
7
Pancreatic Neoplasms
7
Ovarian Neoplasms
7
Gliosarcoma
7
Lung Neoplasms
6
Histiocytoma, Malignant Fibrous
6
Carcinoma, Renal Cell
6
Osteosarcoma
5
Liposarcoma
5
Head and Neck Neoplasms
5
Carcinoma, Hepatocellular
5
Uterine Cervical Neoplasms
4
Sarcoma, Synovial
4
Sarcoma, Kaposi
4
Neurofibrosarcoma
4
Lymphoma
4
Hemangiosarcoma
4
Carcinoma, Merkel Cell
4
Urinary Bladder Neoplasms
3
Stomach Neoplasms
3
Recurrence
3
Interventions
Oncolytic Virotherapy
2
repotrectinib
1
pembrolizumab
1
pamiparib
1
interferon gamma-1b
1
cixutumumab
1
Vincristine
1
Thiotepa
1
Temozolomide
1
Radiation
1
Peripheral Blood Stem Cell Transplantation
1
ONC206
1
Melphalan
1
Interferon-gamma
1
Immunotherapy
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Erlotinib Hydrochloride
1
Doxorubicin
1
Cyclophosphamide
1
Busulfan
1
Bone Marrow Transplantation
1
Antibodies, Monoclonal
1
Amifostine
1
Afatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroectodermal Tumors
×
pembrolizumab
×
Sarcoma
×
Clear all
NCT02798406
2021-07-15
CAPTIVE
DNAtrix, Inc.
Phase 2
Completed
49 enrolled